Welcome to our dedicated page for Vireo Growth news (Ticker: VREOF), a resource for investors and traders seeking the latest updates and insights on Vireo Growth stock.
Vireo Growth Inc. (VREOF) generates a steady flow of news driven by its activities in the cannabis industry, including medical and adult-use operations, multi-state expansion, and corporate transactions. As a company that describes itself as a pioneering medical cannabis operator founded in 2014, Vireo uses press releases to communicate developments in its retail footprint, cultivation and production capacity, and strategic initiatives.
Recent news items highlight several key themes. One is geographic expansion and market entry. Vireo announced an Agreement and Plan of Merger to acquire Eaze Inc., a vertically integrated cannabis retailer and delivery technology platform with operations in California, Florida, and Colorado. The company states that this transaction is intended to mark its entry into California and Florida and to strengthen its position in Colorado, with Eaze becoming a wholly owned subsidiary upon closing.
Another recurring theme is M&A and capital structure activity. Vireo has reported entering into agreements to acquire a majority of Schwazze’s senior secured convertible notes, participating in a restructuring support agreement that contemplates an asset sale to a new entity to be majority-owned by Vireo, and negotiating an Asset Purchase Agreement to acquire Colorado dispensary assets from PharmaCann Inc. These announcements detail transaction terms, consideration in subordinate voting shares, and conditions such as regulatory approvals.
Operational updates also feature prominently. Vireo issued a release announcing the launch of adult-use cannabis sales in Minnesota at its Green Goods dispensaries, noting that it dispenses both medical and adult-use products at eight locations in the state. Quarterly earnings releases provide summaries of financial performance, state-by-state revenue, and non-GAAP metrics, accompanied by management commentary on integration of acquisitions and portfolio development.
Investors and observers who follow VREOF news can use this stream of announcements to monitor transaction progress, regulatory milestones, market entries, adult-use launches, litigation resolutions, and financial reporting updates, all of which are documented through Globe Newswire releases and linked SEC filings.
Vireo Growth (OTCQX: VREOF) entered a definitive Asset Purchase Agreement to acquire certain retail assets and properties of PharmaCann in Colorado for approximately $49.0 million payable in subordinate voting shares, plus assumption of certain liabilities. The acquisition adds 17 dispensaries and expands Vireo’s Colorado footprint to 41 active dispensaries. Share consideration is subject to adjustments for inventory and trade payables and will carry customary Canadian resale and CSE hold restrictions. Parties also signed a Management Services Agreement for Vireo to operate the acquired dispensaries through closing, which is expected in 1H 2026, subject to regulatory approvals and closing conditions.
Vireo Growth (OTCQX: VREOF) reported Q3 2025 GAAP revenue of $91.7M, up 264% year‑over‑year, driven by recent M&A and organic portfolio growth. GAAP gross profit was $37.4M (40.8% margin) and adjusted gross profit was $50.8M (55.4% margin). The company completed refinancing of senior secured debt, which is expected to reduce annualized interest expense by $10M. Cash on hand at September 30, 2025 was $117.5M and total current assets (excl. NY assets held for sale) were $191.1M. Vireo closed transactions to acquire Schwazze secured convertible notes and entered a restructuring plan that contemplates a UCC sale transferring a majority of Schwazze assets to a Vireo‑majority entity. Vireo also reached a settlement with Verano valued at approximately $10M.
Vireo Growth (OTCQX: VREOF) will release third fiscal quarter results for the period ended September 30, 2025 on Wednesday, November 12, 2025 before market open.
Management will host a conference call the same day at 8:30 a.m. ET (7:30 a.m. CT). Dial-in numbers: 1-800-715-9871 (US/Canada toll-free) or 1-646-307-1963 (international toll). Conference ID: 7974705. A live audio webcast will be available in the Events & Presentations section of the company investor relations site and at https://events.q4inc.com/attendee/235390523.
Vireo Growth (OTCQX: VREOF) and Verano Holdings (OTCQX: VRNOF) announced on October 29, 2025 a comprehensive settlement resolving all outstanding litigation between them pending before the Supreme Court of British Columbia.
The settlement, approved by both Boards, provides Vireo with approximately US$10 million in value comprised of certain real estate assets plus US$1 million in cash. The companies said the resolution ends a complex legal chapter and allows both to focus on their strategic priorities and delivering long-term shareholder value.
Vireo Growth (OTCQX: VREOF) closed acquisition of approximately $91,000,000 in senior secured convertible notes of Schwazze (value as of Oct 10, 2025) for total consideration of about $62 million. Vireo issued ~114,807,815 subordinate voting shares to prior noteholders and will assume holders’ rights under the notes, which mature Dec 2026, carry 13.0% interest and are currently in default.
Vireo entered a Restructuring Support Agreement to effect an Asset Sale transferring a majority of Schwazze’s assets (63 dispensaries, 10 manufacturing sites) to a NewCo majority-owned by Vireo, funded in part by up to $62 million of committed financing; remaining Schwazze assets would be wound down. Transactions are subject to closing conditions and regulatory approvals.
Vireo Growth (OTCQX: VREOF) entered definitive agreements on Oct 2, 2025 to acquire ~86% of the outstanding senior secured convertible notes of U.S. multi-state cannabis operator Medicine Man Technologies (dba Schwazze).
The Notes will be purchased at a price substantially below par for total consideration of ~$62 million payable in subordinate voting shares of Vireo at a deemed price of $0.54 per share. The transaction is expected to close later this month and is subject to customary closing conditions, including required approvals.
Vireo Growth (OTCQX: VREOF) has launched adult-use cannabis sales across all eight Green Goods® dispensaries in Minnesota, marking a significant expansion from its existing medical cannabis operations. The company, which has served Minnesota's medical market since 2014, made its first adult-use sale on September 16, 2025, in downtown Minneapolis.
With Minnesota's population of 5.7 million, Vireo expects strong organic revenue growth from this market expansion. The company offers a comprehensive product line including flower, pre-rolls, edibles, and beverages across locations in Minneapolis, Blaine, Bloomington, Burnsville, Duluth, Moorhead, Rochester, and Woodbury.
Vireo Growth (OTCQX:VREOF) has issued a statement in response to a request from the Canadian Investment Regulatory Organization (CIRO) regarding recent market activity. The company confirmed that its management is unaware of any material changes in operations that could explain the recent increase in market activity.
The company included standard forward-looking statements disclaimer, noting that future events may differ from current expectations due to various risks and uncertainties.
Vireo Growth Inc. (OTCQX: VREOF) reported strong Q2 2025 financial results, with GAAP revenue reaching $48.1 million, a 91.4% increase year-over-year. The company completed three significant merger acquisitions in Utah, Missouri, and Nevada, expanding operations to six states. Key financial metrics include Adjusted EBITDA of $13.3 million and pro forma revenue of $90.7 million.
Notably, Vireo secured a $153 million refinancing, comprising a $120 million term loan at 8.3% interest and a $33 million second lien term loan with a $50 million accordion feature. This refinancing is expected to reduce annual interest expenses by over $10 million and has strengthened the company's balance sheet with over $100 million in cash.
Vireo Growth (OTCQX: VREOF) has scheduled its second quarter 2025 financial results release for August 13, 2025, before market opening. The company will host a conference call with investors on the same day at 8:30 a.m. ET to discuss the quarterly performance.
Investors can join the call by dialing 1-800-715-9871 (US/Canada toll-free) or 1-646-307-1963 (International) with conference ID 3718174. A live webcast will be available through the company's Investor Relations website.